2.1. Study Design
PRETERM BIRTH, SECONDARY, PRETERM BIRTH
This is a secondary analysis of diet and supplement intake that was collected prospectively for the primary aim of evaluating how micronutrient intake influenced the effect of docosahexaenoic acid (DHA) supplementation on preterm birth. The multicenter, Phase III, double-blind, randomized clinical superiority trial “The Assessment of DHA on Reducing Early Preterm Birth (ADORE)” was conducted from June 2016 to September 2020 and was supported by the Eunice Kennedy Shriver National Institute of Child Health & Human Development and the Office of Dietary Supplements (R01HD083292). Supplemental funding came from the Office of Dietary Supplements (ODS) (R01 HD083292-03S1) [